Humanpapillomavirusvaccine
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Administer intramuscularly (IM) into the deltoid region of the upper arm (0.5 mL per dose). Age 9 to 14 years: 2-dose schedule at 0 and 6 to 12 months. Age 15 years and older (or immunocompromised): 3-dose schedule at 0, 1 to 2, and 6 months. Shake well before administration. Have the recipient sit or lie down for 15 minutes after vaccination to prevent syncope-related injury.
⚠️ Side Effects
Common: Injection site pain, swelling, erythema, headache, low-grade fever, nausea, dizziness. Rare/Severe: Vasovagal syncope (post-vaccination fainting, especially in adolescents) and severe anaphylaxis.
🛡️ Safety Warnings
Preventive vaccine only; does NOT treat established HPV infections, genital warts, or cervical dysplasia. Observe patient for 15 minutes post-vaccination to prevent falls from vasovagal syncope. Routine cervical cancer screening (Pap smear / HPV DNA testing) must continue unchanged after vaccination.
Jan Aushadhi Products containing Humanpapillomavirusvaccine
Found 1 generic formulation(s) containing this active ingredient.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Humanpapillomavirusvaccine.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (Recombinant) | 0.5 ml in 1 prefilled syringe | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Humanpapillomavirusvaccine generics.